# CHAARTED (E3805)

Source: https://nuclide.cc/trials/chaarted/  
Nuclide record `chaarted` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

The first trial to show chemotherapy at the start of hormone therapy prolongs life in metastatic prostate cancer.

## Summary

CHAARTED, ECOG-ACRIN trial E3805, NCT00309985, reported in 2015, was the first trial to show that giving docetaxel at the start of hormone therapy prolongs life in metastatic hormone-sensitive prostate cancer. It randomised 790 men to androgen deprivation with or without docetaxel and met its primary overall survival endpoint, but in long-term follow-up the benefit was confined to men with high-volume disease. Nuclide links it to prostate cancer, docetaxel and Christopher J. Sweeney, and the result was replicated by arm C of the STAMPEDE platform, with the concentration of benefit in high-volume disease shaping how that distinction is used. Whether chemotherapy still earns its place now that triplet regimens and PSMA radioligands have entered this setting is the open question. Docetaxel has its own page.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-06
- Registry id: NCT00309985
- Phase: 3
- Setting: Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT
- Sponsor: ECOG-ACRIN
- Enrolled: 790
- Result: OS HR 0.61 overall; high-volume HR 0.63; low-volume no benefit.
- Outcomes: Overall survival: ADT + docetaxel 57.6 months vs ADT alone 44 months, HR 0.61
- Replication: Replicated by STAMPEDE arm C; benefit concentrated in high-volume disease.

## Sources

- ClinicalTrials.gov NCT00309985: https://clinicaltrials.gov/study/NCT00309985

## Connected records

- indications: [Metastatic hormone-sensitive prostate cancer](https://nuclide.cc/indications/prostate-mhspc/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- drugs: [Docetaxel](https://nuclide.cc/drugs/docetaxel/)

---
JSON: https://nuclide.cc/api/v1/entities/chaarted.json